Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M13,317Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-879.2EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)20.2Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.310-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %1.6PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M100,000,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with XLV

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
XLVKen Fisher 2016-09-30 Add$71.38 - $75.68
($73.57)
$ 68.41-7%Add 4.23%341,214
XLVKen Fisher 2016-06-30 Add$67.78 - $72.68
($70.43)
$ 68.41-3%Add 9.61%327,373
XLVKen Fisher 2016-03-31 Add$63.52 - $72.03
($67.02)
$ 68.412%Add 1.75%298,675
XLVKen Fisher 2015-12-31 Add$66.86 - $72.99
($70.76)
$ 68.41-3%Add 2.64%293,541
XLVKen Fisher 2015-09-30 Add$64.29 - $77.22
($73.06)
$ 68.41-6%Add 5.33%285,985
XLVLeon Cooperman 2015-06-30 Sold Out -0.42%$71.46 - $76.45
($73.85)
$ 68.41-7%Sold Out0
XLVKen Fisher 2015-06-30 Add$71.71 - $76.45
($74.07)
$ 68.41-8%Add 5.40%271,515
XLVLeon Cooperman 2015-03-31 Buy 0.42%$67.86 - $74.9
($71.15)
$ 68.41-4%New holding366,000
XLVKen Fisher 2015-03-31 Add$68.05 - $74.9
($71.32)
$ 68.41-4%Add 4.15%257,614
XLVKen Fisher 2014-06-30 Add0.01%$55.71 - $61.23
($58.7)
$ 68.4117%Add 34.36%226,412
XLVGeorge Soros 2012-09-30 Sold Out -0.03%$37.27 - $40.3
($38.73)
$ 68.4177%Sold Out0
XLVGeorge Soros 2012-06-30 Buy 0.03%$35.52 - $37.87
($36.91)
$ 68.4185%New holding50,000
XLVKen Fisher 2012-06-30 Add$35.52 - $37.87
($36.91)
$ 68.4185%Add 53.52%119,754
XLVKen Fisher 2011-06-30 Buy 0.01%$33.28 - $36.42
($34.99)
$ 68.4196%New holding86,997
XLVGeorge Soros 2011-03-31 Sold Out $31.5 - $33.18
($32.33)
$ 68.41112%Sold Out0
XLVGeorge Soros 2010-12-31 Reduce-0.15%$30.19 - $31.78
($31.13)
$ 68.41120%Reduce -93.88%34,153
XLVGeorge Soros 2010-09-30 Buy 0.25%$28.03 - $30.68
($29.2)
$ 68.41134%New holding558,053
XLVGeorge Soros 2010-06-30 Sold Out $28.38 - $32.31
($30.13)
$ 68.41127%Sold Out0
XLVGeorge Soros 2010-03-31 Reduce$30.68 - $33
($31.72)
$ 68.41116%Reduce -43.59%6,600
XLVGeorge Soros 2009-12-31 Buy 0.01%$28.07 - $31.62
($30.04)
$ 68.41128%New holding11,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XLV is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


XLV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Brown, ArthurDirector, Senior Officer 2016-11-08Buy25,000$0.2824332.14view
BACH, WENDYSenior Officer 2016-11-08Sell3,549$48.0642.34view
BACH, WENDYSenior Officer 2016-11-08Buy4,619$48.0842.28view
BACH, WENDYSenior Officer 2016-11-08Sell1,070$48.0642.34view
Miller, James MichaelSenior Officer 2016-11-08Buy5,000$4.31490.93view
Omni-Lite Industries Canada InIssuer 2016-11-08Buy2,300$1.654046.06view
PAMPLIN, Ann-Marie MichelleDeemed Insider - 6 Months before becoming Insider 2016-11-08Buy13,000$0.1352523.08view
Glazier, Patrick L.Director 2016-11-08Buy100,000$0.1448764.29view
Sutton, Brayden RobertDirector 2016-11-08Buy5,000$0.2824332.14view
Reilly, Robert BruceSenior Officer 2016-11-08Sell155,000$0.06113916.67view

Quarterly/Annual Reports about XLV:

    News about XLV:

    Articles On GuruFocus.com
    S&P 500 Sector ETFs: A Look Under the Hood, Part 3 Mar 11 2015 
    Build a “Whatever Happens” Portfolio – Now! Aug 15 2014 
    Are Earnings Important? These Days, Revenues Count for More! Mar 17 2014 

    More From Other Websites
    The Fuel for Today’s Reflationary Fire: What You Need to Know Dec 02 2016
    Which US Sectors Look Appealing in the Reflationary Environment? Dec 02 2016
    Keytruda Is Merck’s Immuno-Oncology Business Dec 02 2016
    The controversial medical association that counts Trump nominee Tom Price among its members Dec 02 2016
    What Do Analysts Recommend for Boston Scientific? Nov 30 2016
    What Are Analysts’ Recommendations for Thermo Fisher Scientific? Nov 30 2016
    Scrutinizing the HCV Market Based on Genotypes Nov 30 2016
    Markets Set Chance of Fed Rate Hike at 90% Nov 30 2016
    Analyzing Allergan’s Growth Pharma Plans Nov 29 2016
    What Really Disrupted Medtronic’s Diabetes Segment Sales in Fiscal 2Q17? Nov 29 2016
    Acthar’s Higher Exposure to Government-Oriented Franchise Nov 29 2016
    Humira Has Been a Key Growth Driver for AbbVie in 2016 Nov 28 2016
    How Did Bristol-Myers Squibb’s Virology Segment Perform in 3Q16? Nov 28 2016
    What Eli Lilly’s hard fall in Alzheimer’s treatment race means for its competitors Nov 25 2016
    This Is Eli Lilly’s Animal Health Segment Nov 24 2016
    Health Care ETFs Fall As Eli Lilly, Juno Add To Troubled Sector's Woes Nov 23 2016
    BMY’s Orencia Has Been Approved to Treat Methotrexate-Naive Patients Nov 23 2016
    This underperforming sector means good things for the rest of the market Nov 22 2016
    How Stocks and Bonds Reacted to Trump’s Victory Nov 22 2016
    Bristol’s Opdivo Has One Eye on Advanced Bladder Cancer Nov 22 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)